This is a paid press release. Contact the press release distributor directly with any enquiries.
Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day
Veru Inc.
Tue, 7 July 2026 at 6:00 pm GMT+5:30
10 min read
- VERU
-7.52%
MIAMI, FL, July 07, 2026 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced it will present at the 2026 4th Annual Obesity & Weight Loss Drug Development Summit, and the Pre-Conference Workshop Day taking place on July 14-16, 2026, in Boston, Massachusetts
2026 Obesity & Weight Loss Drug Development Summit
Program: Integrating Age-Specific Clinical Protocols to Address Unique Physiological Risks in Paediatric & Geriatric Patients, for Safer, More Effective Treatments
Presentation Title: Combating Sarcopenic Obesity in Geriatrics by Combining GLP-1s with Selective Androgen Receptor Modulators (SARMs) to Prevent Muscle Loss
Presenter: Mitchell Steiner, MD, Veru Inc.’s Chairman, President & CEO
Presentation Date & Time:July 15, 2026 at 4:20 PM Eastern Daylight Time
2026 Obesity & Weight Loss Drug Development Summit – Pre-Conference Workshop Day
Session Title: Moving Beyond BMI & Weight-Loss Endpoints to Advance the Regulatory Frontier & Redefine Clinical Success with the FDA
Presenters:Gary Barnette, PhD, Veru Inc.’s Chief Scientific Officer
Session Date & Time:July 14, 2026 at 1:30 PM Eastern Daylight Time
Additional information on the meeting can be found on the following website: https://obesity-weight-loss-summit.com/
About Veru Inc.Veru is a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases. The Company’s drug development program includes two late-stage novel small molecules, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator (SARM), is being developed as a next generation drug that makes weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass to improve body composition and physical function which is expected to result in clinically meaningful incremental weight reduction versus GLP-1 RA therapy alone. Sabizabulin, a microtubule disruptor, is being developed for the treatment of chronic inflammation related to atherosclerotic cardiovascular disease.
Veru Obesity Program: Study of Enobosarm in combination with GLP-1 RA for higher quality weight reduction
Enrolling Phase 2b PLATEAU Clinical StudyPhase 2b PLATEAU clinical trial is a double-blind, placebo-controlled study to evaluate the effect of enobosarm 3mg on total body weight, fat mass, lean mass, physical function, bone mineral density and safety in approximately 200 older patients (age ≥ 65 years) who have obesity (BMI ≥ 35) and are initiating semaglutide treatment for weight reduction. The Phase 2b PLATEAU study is designed to assess the ability of enobosarm treatment to break through the weight loss plateau observed in patients with obesity receiving GLP-1 RA treatment by preserving muscle mass and physical function to achieve clinically meaningful incremental weight reduction by 68 weeks.
